Insight into the WNT system and its drug related response

S. Tamanini, L. Idolazzi, D. Gatti, O. Viapiana, A. Fassio, M. Rossini
Rheumatology Unit, University of Verona, Italy

SUMMARY
The WNT signalling pathway is a complex system for transferring information for DNA expression from the cell surface receptors to cytoplasm and then to the nucleus. It is based on several proteins that work together as agonists and antagonists in order to maintain homeostasis and to promote anabolic processes. The WNT system acts on all cellular lines involved in bone resorption and formation. WNT pathway can mainly be triggered by two different signalling cascades. The first is well known and is the so-called WNT-beta catenin system (or the canonical pathway), the second is known as the non canonical WNT pathway. WNT proteins form a superfamily of secreted glycoproteins. The association with surface receptors, called Frizzled, that are members of the G protein-coupled receptors superfamily and co receptors like low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6) complete the WNT system. LRP5/6 show high affinity for WNT antagonists that modulate the activity of this pathway: DKK1 and sclerostin (SCL), that play a crucial role in modulating the WNT system. The WNT-pathway and in particular its antagonists SCL and DKK1 seems to play a key role in the regulation of bone remodeling during treatment with bone active agents such as bisphosphonates, but not only. Their effects become relevant especially in the course of long-term treatments.

Key words: WNT, DKK1, Sclerostin, Bisphosphonate.

INTRODUCTION

This year is the thirtieth anniversary of the published report that announced the discovery of what proved to be the first mammalian WNT gene involved in mouse breast cancers with the evidence of its rule as proto-oncogene transcriptionally activated by viruses in multiple independent tumors (1).

Since then it was clear that WNT genes and components of WNT signalling pathways are implicated in a wide spectrum of important biological phenomena, ranging from early organ development to cell behaviour in several diseases, not only cancers.

The WNT signalling pathway is a complex system for transferring information for DNA expression from the cell surface receptors to cytoplasm and then to the nucleus.

WNTs are a large family of 19 secreted glycoproteins that trigger multiple signalling cascades that are essential for embryonic development and tissue regeneration (2). WNTs represent the driving system of the embryo and determine body axes and drive organs growing in the right direction (3). In addition, WNT signalling orchestrate morphogenesis during embryonic development and this signalling pathway is critical for the maintenance of adult stem cell compartments in the bone, hematopoietic and gastrointestinal system. Another important task of WNT system is the maintenance of self-renewing tissues such as bone marrow, gut and skin.

The WNT pathway is a rather complex signalling system. On the plasma membrane of mammalian cells, any combination of 19 soluble WNT ligands and 10 WNT receptors of the Frizzled (FZ) protein family and several co-receptors and at least four classes of secreted WNT signalling modulators [secreted FZ-related protein family (SFRP), Dickkopfs (Dkk), Rpondins and WIF] can be present (4).

Aberrant WNT signalling results in developing malformation and underlies different human pathologies such as colorectal cancer, osteoporosis and neurodegenerative disorders (3). Proteins involved in the am-
plification and transduction of WNT signals are often altered in cancer or lineage progenitor cells, leading to abnormal cell cycle control and/or altered cell fate decisions. Any mutations in several WNT pathway components might also contribute to human skeletal dysplasia (2) (Tab. I).

## WNT AND BONE

The molecular links between WNT signalling and bone development and remodelling were discovered by observing mutations in the WNT coreceptor low-density lipo-protein receptor-related protein 5 (LRP5). These mutations are linked to alterations in human bone mass (5-8). The discovery that activating and inactivating mutations in a WNT co-receptor can lead both to high bone mass and low bone mass in human beings, demonstrated that WNT signalling is a dominant regulator of bone density in humans and this point was then confirmed also in mouse genetic studies (9). Even small changes in the intensity, amplitude and duration of WNT signalling are able to interfere with skeletal development as well as bone remodelling, regeneration and repair during life. In addition, a number of polymorphisms in different WNT pathway

<table>
<thead>
<tr>
<th>Gene</th>
<th>Altered function</th>
<th>Type of alteration</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>PORCN</td>
<td>Enhancing WNT lipid modification/processing</td>
<td>LOF</td>
<td>X linked focal dermal hypoplasia</td>
</tr>
<tr>
<td>Wnt3</td>
<td>Enhancing ligands for WNT signaling</td>
<td>LOF</td>
<td>Tetramelia</td>
</tr>
<tr>
<td>Wnt4</td>
<td>Enhancing ligands for WNT signaling</td>
<td>LOF</td>
<td>Mullerian-duct regression and virilization</td>
</tr>
<tr>
<td>Wnt5b</td>
<td>Enhancing ligands for WNT signaling</td>
<td>Unknown</td>
<td>Type II diabetes</td>
</tr>
<tr>
<td>Wnt7a</td>
<td>Enhancing ligands for WNT signaling</td>
<td>LOF</td>
<td>Fuhrmann syndrome</td>
</tr>
<tr>
<td>Wnt10a</td>
<td>Enhancing ligands for WNT signaling</td>
<td>LOF</td>
<td>Odonto-onycho-dermal hypoplasia</td>
</tr>
<tr>
<td>Wnt10b</td>
<td>Enhancing ligands for WNT signaling</td>
<td>LOF</td>
<td>Obesity</td>
</tr>
<tr>
<td>RSPO1</td>
<td>Enhancing WNT agonists</td>
<td>LOF</td>
<td>XX sex reversal - Hyperkeratosis</td>
</tr>
<tr>
<td>RSPO4</td>
<td>Enhancing WNT agonists</td>
<td>LOF</td>
<td>Autosomal recessive anonychia-hyponychia congenita</td>
</tr>
<tr>
<td>SOST</td>
<td>Inhibition of LRP 5/6 antagonists</td>
<td>LOF</td>
<td>Sclerostosis/Van Buchem disease</td>
</tr>
<tr>
<td>Norrin (NDP)</td>
<td>Enhancing specific ligands during eye development</td>
<td>LOF</td>
<td>-</td>
</tr>
<tr>
<td>LRP5</td>
<td>Enhancing WNT coreceptors</td>
<td>GOF</td>
<td>Hyperparathyroid tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High bone mass</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Osteoporosis-pseudoglioma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>FEVR eye vascular defects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Early coronary disease and osteoporosis</td>
</tr>
<tr>
<td>LRP6</td>
<td>Enhancing WNT coreceptors</td>
<td>LOF</td>
<td>Early coronary disease and osteoporosis</td>
</tr>
<tr>
<td>FZD4</td>
<td>Enhancing WNT receptors</td>
<td>LOF</td>
<td>Familial exudative vitreoretinopathy</td>
</tr>
<tr>
<td>Axin 1</td>
<td>Inhibition of beta-catenin degradation</td>
<td>LOF</td>
<td>Caudal duplication, cancer</td>
</tr>
<tr>
<td>Axin 2</td>
<td>Inhibition of beta-catenin degradation</td>
<td>LOF</td>
<td>Tooth agenesis, cancer</td>
</tr>
<tr>
<td>APC</td>
<td>Inhibition of beta-catenin degradation</td>
<td>LOF</td>
<td>Familial adenomatous polyposis, cancer</td>
</tr>
<tr>
<td>WTX</td>
<td>Inhibition of beta-catenin degradation</td>
<td>LOF</td>
<td>Wilms tumor</td>
</tr>
<tr>
<td>Beta-catenin (CTNNB1)</td>
<td>Enhancing of pro oncogene action</td>
<td>GOF</td>
<td>Cancer</td>
</tr>
</tbody>
</table>

LOF: loss of function; GOF: gain of function; LRP: low-density lipoprotein receptor; FEVR: familial exudative vitreoretinopathy. Modified from MacDonald et al., 2009 (47).
components have been identified and found to be linked to altered bone mineral density (10-14). So in the last few years the interest for the WNT signalling pathways has been growing for their relevance in skeletal development, bone mass maintenance and potential therapeutic implications. The WNT pathways involve all bone cells: osteoblasts, osteocytes and osteoclasts. Mesenchymal stem cells (MSC) resident in the bone cavity give rise to most narrow stromal cell lineages, including chondrocytes, osteoblasts, fibroblasts, adipocytes, endothelial cells, and myocytes (15). Osteoblasts are responsible for bone formation. Osteocytes are terminally differentiated osteoblasts embedded within the mineralized matrix that communicate changes in mechanical loading and extracellular environment to osteoblasts and osteoclasts on bone surface and so regulate bone remodeling and fracture repair (16). Osteoclasts originate from hematopoietic stem cells and are responsible for bone resorption (17). Several basic studies have suggested that WNT signalling enhances bone formation by regulating osteoblast and osteoclast proliferation and differentiation through well-characterized steps:

1) WNT signalling is crucial for the differentiation of osteoblasts from mesenchymal precursors (18), by shifting MSC differentiation from chondrocyte and adipocyte to osteoblast (19-23);

2) WNT signalling is associated with proliferation, maturation and survival of osteoblasts. A subgroup of WNT induces a cascade of intracellular events that stabilize beta-catenin, facilitating its transport to nucleus where it binds Lef1/Tcf transcription factors and alters gene expression to promote osteoblast expansion, proliferation, function, and survival (24);

3) WNT signalling is also implicated in the coupling of osteoblast and osteoclast activity. The enhancing osteoblast differentiation ensues in increased synthesis and secretion of osteoprotegerin (OPG), a competitive inhibitor of receptor activator of nuclear factor kappa B (RANKL). It also interferes with RANK-RANKL interaction which is essential for osteoclast maturation and activity. In this way WNT, indirectly, can block osteoclast differentiation. Thus, WNT signalling may be associated with both increased bone formation and inhibition of osteoclast-mediated bone resorption (25).

### THE WNT PATHWAYS

WNTs trigger different signalling cascades. We can distinguish two different pathways: canonical and non-canonical which are depending on the typology of WNT, cell surface receptors present on recipient cells and on local concentration of WNT antagonists.

The canonical WNT-beta catenin signalling

The best-known pathway is the so-called canonical pathway that leads to stabilization and nuclear translocation of the beta-catenin, normally present in the cytoplasm. A key component of canonical WNT pathway is Axin which negatively regulates WNT signalling by facilitating the phosphorylation and degradation of beta-catenin. In absence of WNTs, beta-catenin is quickly sequestered and degraded by ubiquitin-mediated proteolysis (2, 24).

Binding of certain WNTs (e.g. WNT3a) with specific cell surface receptors leads to inactivation of beta-catenin proteolysis also through the degradation of Axin (26). This way beta-catenin becomes stable, its cytoplasmic levels are increased and it can enter in the nucleus where it regulates the expression of target genes displacing co-repressors from transcriptional factors (2).

The WNT canonical pathway contributes to differentiation, proliferation and survival of osteoblasts (24) and it regulates the expression of OPG inhibiting osteoclast-mediated bone resorption (25).

WNT pathways play a key role in determining the fate of MSC. In absence of beta-catenin these cells do not differentiate into mature osteocalcin-expressing osteoblasts (19, 20) but only into chondrocytes. On the contrary,
WNT canonical signalling prevents progenitor cells differentiating down the chondrocyte lineage and targeting them instead to the osteoblast lineage (21, 22). WNT signalling pathways promote osteoblastogenesis also by suppressing adipogenesis. Inducers of differentiation in one lineage often inhibit differentiation along the others. Thus, for example, peroxisome proliferator activated receptor gamma (PPAR-gamma) is a transcription factor that induces adipogenesis and inhibits osteoblastogenesis (27). Both canonical and non-canonical WNT pathways induce osteoblastogenesis and suppress adipogenesis by reducing the expression of PPAR-gamma (23, 28) (Fig. 1).

The WNT-non-canonical pathways
Sometimes WNTs do not activate the beta-catenin canonical pathway but they rather trigger alternative intracellular events (non-canonical pathways). Beta-catenin independent signalling are mediated by several kinases such as mitogen-activated protein, protein kinase and calcium/calmodulin-dependent protein kinase (23). These pathways regulate cellular proliferation, differentiation, migration and polarity (2). The effects on bone are subjected to intensive investigation but it is likely that also non-canonical WNT signalling supports normal bone physiology in adults. In this context it should be emphasized that non-canonical WNT ligands and their receptors are expressed in adult bone at level comparable to those for canonical WNT signalling pathways (23) but its role in supporting osteoblastogenesis is still poorly understood. A non-canonical WNT ligand (WNT5A) strongly suppresses transcription of PPAR-gamma and has emerged as an MSC fate determinant through shifting MSC differentiation from adipocyte to osteoblast (29). The timing of this non-canonical WNT action seems to be critical in inducing osteoblastogenesis over adipogenesis (23).

Tipology of WNT
WNTs are a family of secreted glycoproteins. The processing and secretion of all WNTs are under the control of seven-pass-transmembrane protein called WNTless (30-32) that is expressed ubiquitously in human and rodent cells (33, 34). This indicates that WNTs are important for all cell type both during foetal and postnatal growth. Cells recognize WNTs through 10 Frizzled receptors and their co-receptors low-density lipoprotein receptor-related protein: LRP5 or LRP6 and potentially LRP4 (2). The large number of ligands and receptors and of their possible combinations contributes to widely variable cellular responses depending on the molecules present. Historically, two different metabolic pathways (canonical and non-canonical) were identified based on their ability to activate beta catenin. In general, WNT1, WNT3a, WNT5a, WNT7a, WNT8a and WNT10a are considered activators of the canonical pathway, whereas WNT5a or WNT11 are best known for their ability to trigger non-canonical WNT signalling (23, 35). This distinction is not so clear since some WNTs may activate both pathways depending on the cellular context and the presence of appropriate Frizzled receptors (2, 35).
**WNT-RECEPTORS**

### Frizzleds

WNTs exert their biological effects by binding and then activating cell surface receptors, called Frizzled, that are members of the G protein-coupled receptors superfamily. Like the other G protein-coupled receptors also Frizzleds can be considered membrane receptors with three basic regions (36):

1. **the N-terminal, exofacial domains.** These participate in binding WNT or other antagonists, with and without co-receptors like LDL receptor-related proteins: LRP5/6. The latter include members of the SFRP, of the Dkk family ligands and sclerostin (SCL) (36).

   Activation of the canonical pathway is initiated when WNT associates with FZ and LRP5/6, while the activation of non-canonical pathway seems to involve interaction of WNT with FZ but in absence of LRP5/6 (37);

2. **a transmembrane central core composed of seven, hydrophobic alpha-helices that span the lipid bilayers;**

3. **at least three intracellular loops and a C-terminal tail that constitute the cytoplasmic domains.** They are intimately involved in signal propagation first to heterotrimeric G-proteins and then to downstream signalling elements found in the cellular cytoplasm (36, 38).

### Low-density lipoprotein receptor-related proteins

Low-density lipoprotein receptor-related proteins are plasma membrane receptors involved in lipid metabolism, transport and cellular signalling. The initiation of the WNT-beta catenin signalling cascade takes place when FZ form a complex together with WNT-ligands and with the WNT-coreceptors LRP5 or LRP6. These co-receptors exhibit a highly conserved domain structure and consist of a large extracellular domain, a small transmembrane region and a cytoplasmatic domain (39-41). LRP5 and 6 show low affinity for WNTs and high affinity for soluble antagonists such as SCL and Dkk1 (2) which are therefore essential for the regulation of WNT activation and inhibition.

LRP5 is required for efficient WNT signalling and beta-catenin activation in osteoblasts (2). It plays a key role in regulation of bone mass either through a direct control of osteoblast-lineage cells or indirectly in endocrine and paracrine manner, controlling bone formation by inhibiting serotonin synthesis in the duodenum (42).

LRP6 share 70% amino acid identity with LRP5 and has many similar properties. This co-receptor contributes also to optimal parathyroid hormone (PTH) signalling in osteoblasts (43). Recently it has been shown that LRP6 plays an essential role in WNT3a/beta catenin signalling and inhibition of adipogenic differentiation of stem cells actions that cannot be replaced by LRP5 (44).

LRP4 is an emerging regulator of bone mass. It can antagonize canonical WNT pathway *in vitro* (45) and modulates several signalling pathways in skeletal and tooth development especially in craniofacial organogenesis (46).

The loss of function in *LRP5* gene is involved in the osteoporosis pseudoglioma syndrome, a recessive disorder characterized by low bone mass and abnormal eye vasculature (5, 47, 48). Conversely patients with autosomal dominant high bone mass diseases harbor LRP5 missense (gain-of-function) mutations (49), which are clustered in the LRP5 extracellular domain and render LRP5 resistant to binding and inhibition by the antagonist SOST (50, 51) and DKK1 (52).

### WNT-antagonists

Secreted WNT antagonists can inhibit WNT signalling by binding either WNTs or LRP5/6 co-receptors, leading in both cases to inhibition of the aggregation of the 3 components of the WNT pathway.

#### Secreted frizzled-related proteins

Secreted frizzled-related proteins (SFRPs) include 5 members of secreted, cysteine-rich glycoproteins SFRPs that directly bind to WNTs/FZ complex, preventing their functional association with FZs on the cell
surface (37). SFRP1 is the most extensively studied and its cysteine rich domain has homology with the FZ-WNT receptor (53, 54). Study on KO animals and cell cultures showed that the lack of SFRP1 is associated with high trabecular bone density similar to that seen during treatment with PTH (55,56) while its overexpression in mice is associated with decreased bone density and with the prevention of the anabolic effect of PTH (57). SFRP1 might be involved also in glucocorticoid induced osteoporosis since its expression is increased by dexamethasone (58). It was also suggested that SFRP1 may also bind RANKL and then block osteoblast-induced osteoclastogenesis (59). This way SFRP1 might inhibit both osteoblast and osteoclast activity (58).

**Dickkopfs**

The Dickkopfs family comprises four members (Dkk1 to Dkk4) and a unique Dkk3 related protein named Soggy (37). DKK1 is the most studied member of the family, it is expressed and active in many tissue (60) and regulates bone mass in human. Dkk1 inhibits WNT-induced stabilisation of beta catenin by binding to LRP5/6. Dkk1 also interacts with another class of receptors (Kremen 1 and 2) to form a ternary complex (Kremen-Dkk1-LRP6) that blocks WNT-LRP6 signalling by inducing endocytosis and removal of WNT receptors from the plasma membrane (61). The internalisation of LRP5/6 with Kremen receptors seems to inhibit the degradation of Axin. Then it promotes the degradation of beta-catenin in order to inhibit the canonical WNT pathway (37). The antagonistic effect of Dkk1, mediated by LRP5/6, might be specific to the WNT beta-catenin pathway since the activation of non-canonical WNT pathway is not affected (62). Dkk1 counteracts the WNT-beta-catenin effects on bone differentiation by promoting adipogenesis (60). WNT Beta-catenin pathway activation not only stimulates new bone formation but it also inhibits osteoclastogenesis by increasing OPG, the decoy protein for RANKL (25). In addition to bone formation impairment, Dkk1 overexpression shifts the OPG:RANKL ratio to favour bone resorption. At variance with SFRP which blunts both bone formation and bone resorption, Dkk1 inhibits bone formation and favours osteoclastic bone resorption.

The role played by other DKKs is less clear. The activity of Dkk3 and 4 appear similar to the Dkk1 one, but is apparently not expressed by bone cells (2). The molecular functions of Dkk2 are more complicated and vary with cellular context. Both Dkk1 and Dkk2 can bind to LRP6 (61) but Dkk2 can either antagonise either stimulate (37) WNT beta-catenin pathway. These opposing effects may be modulated by Kremen 2 which converts Dkk2 from agonist to antagonist of LRP6 (63). Moreover in the presence of high WNT7b levels DKK2 induce terminal osteoblast levels DKK2 induce terminal osteoblast differentiation (64).

**Sclerostin**

Bone remodeling is the physiological process by which bone tissue is continually removed and replaced on the surface of trabecular bone and within the Haversian systems of cortical bone. This process requires the activity of three different types of cells - osteoclasts (bone resorbing cells), osteoblasts (bone forming cells), and osteocytes. Osteocytes are former osteoblasts that were trapped in the newly formed bone matrix. They communicate with one another and with bone lining cells of bone surface through a network of cytoplasmic connections (65) and are cells that detect loads applied to bone. Over loading is associated with local stimulation of bone formation and vice-versa. This mechanoregulatory mechanism is mediated by SCL expressed almost uniquely by osteocytes.

Sclerostin is a monomeric glycoprotein that antagonizes WNT/beta-catenin signalling (66) in osteoblasts as DKK1, by binding to LRP5 and LRP6 and preventing their association with FZ and WNTs. This results in the inhibition of osteoblast differentiation, activity, and survival (67). SCL is the product of the SOST gene, which is mutated and down-regulated in patients with sclerosteosis and van Buchem’s dis-
Insight into the WNT system and its drug related response

As it often happens, identification of the genetic and molecular origin of a rare disease has revealed an important mechanism in normal physiological processes with potential implication for the development of new treatments for common diseases. The concept that osteocytes have a mechanosensing role with sclerostin as a key signalling protein for osteoblasts is supported by several preclinical studies (71). Bone loading in animals is associated with decreased expression of SCL by osteocytes and with an increase in bone formation while bone unloading is associated with an increase in SOST transcription (72), up-regulation of sclerostin, and a decrease in WNT/beta-catenin signalling (73).

Bone density and mechanical strength are elevated in Sost knockout mice (74, 75) whereas transgenic overexpression of Sost induces osteopenia (76, 77). All these data suggest that disuse osteoporosis may in part be mediated by sclerostin-related inhibition of osteoblastic bone formation and that SCL is an important negative regulator of bone formation. Evidence points out that in addition to its anti-anabolic role, sclerostin has a catabolic activity. Sclerostin dose-dependently up-regulates the expression of RANKL mRNA and down-regulates the expression of OPG mRNA, causing an increase in the RANK:OPG mRNA ratio (78), enhancing osteoclast activity. This action seems similar to DKK1 and is due to the inhibition of WNT canonical pathway in which beta-catenin induces an increase in synthesis and secretion of OPG (25).

SCL seems also to be an important mediator of the anabolic effect of PTH in bone. PTH suppresses SCL expression both in vitro and in vivo (79, 80) while over-expression of SOST prevent in rats the anabolic response to PTH administration (81, 82). Unlike DKKs and SFRP, SCL is produced primarily by bone cells and is abundant especially in the osteocytic canalicular system (83, 84) SCL has also been detected in cementocytes in teeth, mineralized hypertrophic chondrocytes in the growth plate, and osteoarthritic cartilage (85, 86). SCL may also be expressed by osteoclast precursors but not in by mature osteoclasts (87).

The WNT pathway with their several components seem to have a key role in bone development, remodeling, and repair although there is still much to understand and to study and much remains to be discovered. However already now our knowledge allows us to recognize this pathway as a possible source of new therapeutic strategies for common disease characterized by altered bone mass as osteoporosis, of high socioeconomic burden (88). Some of these treatments are already in advanced stage of development (89). Moreover this pathway is probably involved in the metabolic response to treatment with bone active agents used for the treatment of post-menopausal and male osteoporosis (90). In fact some of their effects on bone turnover are related with changes in the WNT/beta-catenin signalling. For example treatment with estrogens or raloxifene, but

Figure 2 - The increase in serum sclerostin during treatment with neridronate versus placebo. The association between neridronate treatment and increased sclerostin levels suggests that the inhibition of bone formation observed after extended treatment with bisphosphonates might be mediated, at least in part, by an increase in sclerostin (modified from Gatti et al., 2011 (94)).
not with androgens, is associated with a decrease in SCL levels (91, 92).
For this reason we decided to study both the changes in the WNT-antagonists serum levels (SCL and DKK1) during antiresorptive (bisphosphonates and denosumab) and anabolic treatment (teriparatide) (93).
Bisphosphonates are known to directly suppress osteoclastic activity, but the suppression of bone resorption is typically associated with a later decrease of bone formation.
To determine whether this decrease in bone formation is associated with changes in serum levels of SCL or DKK1, 107 patients were treated with either monthly intramuscular neridronate or placebo (88). Serum C-terminal telopeptide of type I collagen (sCTX, a bone-resorption marker) and bone alkaline phosphatase (bAP, a bone-formation marker) decreased, as expected, during neridronate treatment. Serum DKK1 remained unchanged at all time points while serum SCL increased versus placebo group gradually and significantly only in patients treated with two upper doses (25 or 50 mg neridronate monthly), reaching 138-148% of baseline values (P<0.001) (Fig. 2). In consideration of the anti-anabolic effects of sclerostin on bone formation, the association between neridronate treatment and increased sclerostin levels suggests that the inhibition of bone formation observed after extended treatment with bisphosphonates might be mediated, at least in part, by an increase in sclerostin. Indeed we found a negative correlation (P<0.001) between the changes in bAP and sclerostin but causal link remains hypothetical (94).
This effect of bisphosphonates on WNT-antagonist appears to be different from that we found in patients treated with denosumab (95), an antiresorative drug that, suppressing RANKL activity, lowers the number not only of actively resorbing osteoclasts (as bisphosphonates do) but also of osteoclast precursors. In our study denosumab therapy was found to be associated with increasing SCL levels (as bisphosphonates treatment) but it was also associated with declining serum levels of DKK1 (95) and this might explain the apparent persistent slight positive unbalance between suppressed bone resorption and formation during denosumab treatment (96).
The WNT-pathway is also involved in the response to bone anabolic agents. It has been reported that treatment with analogs of PTH or teriparatide is associated with decreases in serum SCL (97-99). These observations strongly suggest that the positive effect of PTH on osteoblast activity is at least in part mediated by changes in the WNT/β catenin signalling. It was also found that the effect of teriparatide on SOST disappears within a few months and that long-term treatment is associated with an increase in DKK1 (100). This might explains the loss of the bone anabolic effect of teriparatide after 18-24 months of continuous treatment.
In conclusion the WNT-pathway and in particular its antagonists SCL and DKK1 seems to play a key role in the regulation of bone remodeling in a number of clinical conditions and during treatment with bone active agents, such as bisphosphonates, but not only. Their effects become relevant especially in the course of long-term treatments.

REFERENCES

6. Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated mis-
21. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005; 8: 739-50.
el transmembrane protein required for Wg secretion and signaling. Development. 2006; 133: 4901-11.


51. Semenov MV, He X. LRPS mutations linked to high bone mass diseases cause reduced LRPS binding and inhibition by SOST. J Biol Chem. 2006; 281: 38276-84.


57. Wang F-S, Lin C-L, Chen Y-J, Wang C-J,
Insight into the WNT system and its drug related response


100. Gatti D, Idolazzi L, Fracassi E, Rossini M, Adami S. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011; 96: 1555-9.0